- Home
- MMA vs MBRX Comparison
MMA vs MBRX Comparison
Compare MMA & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | MBRX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.7M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MMA | MBRX |
|---|---|---|
| Price | $0.42 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 15.8M | 692.4K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.16 |
| 52 Week High | $2.00 | $7.98 |
Technical Indicators
Market Signals| Indicator | MMA | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 49.75 |
| Support Level | $0.36 | $0.16 |
| Resistance Level | $0.44 | $2.26 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 12.63 | 97.78 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.